The Concept of Multiple-Target Anti-miRNA Antisense Oligonucleotide Technology

Methods in Molecular Biology

Volumn 676, Issue , 2011, Pages 51-57

  Wang, Zhiguo ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

Author keywords

AMO; miRNAs; Multiple target AMO technology; One drug, multiple targets

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; MICRORNA;

ANIMAL; ARTICLE; GENETICS; HUMAN;

ANIMALS; HUMANS; MICRORNAS; OLIGONUCLEOTIDES, ANTISENSE;

MLCS; MLOWN;

EID: 79952197420     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-60761-863-8_4     Document Type: Chapter

References (27)

1. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M (2005) Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438:685–689.
2. Hammond SM (2006) MicroRNA therapeutics: a new niche for antisense nucleic acids. TiMM 12:99–101.
3. Cheng AM, Byrom MW, Shelton J, Ford LP, Cheng AM, Byrom MW, Shelton J, Ford LP (2005) Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 33:1290–1297.
4. Stenvang J, Kauppinen S (2008) MicroRNAs as targets for antisense-based therapeutics. Expert Opin Biol Ther 8:59–81.
5. Eckstein F (2007) The versatility of oligonucleotides as potential therapeutics. Expert Opin Biol Ther 7:1021–1034.
6. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116:258–267.
7. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103: 18255–18260.
8. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M (2007) MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100:416–424.
9. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613–618.
10. Cheng Y, Ji R, Yue J, Yang J, Liu X, Chen H, Dean DB, Zhang C (2007) MicroRNAs are aberrantly expressed in hypertrophic heart. Do they play a role in cardiac hypertrophy? Am J Pathol 170:1831–1840.
11. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ (2007) Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42:1137–1141.
12. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 103:2257–2261.
13. Krek A, Grun D, Poy M, Wolf R, Rosenberg L, Epstein E, MacMenamin P, da Piedade I, Gunsalus K, Stoffel M, Rajewsky N (2005) Combinatorial microRNA target predictions. Nat Genet 37:495–500.
14. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, Zhai Y, Giordano TJ, Qin ZS, Moore BB, MacDougald OA, Cho KR, Fearon ER (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17:1298–1307.
15. Ebert MS, Neilson JR, Sharp PA (2007) MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods 4:721–726.
16. Bartel DP, Chen CZ (2004) Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 5:396–400.
17. Vermeulen A, Robertson B, Dalby AB, Marshall WS, Karpilow J, Leake D, Khvorova A, Baskerville S (2007) Double-stranded regions are essential design components of potent inhibitors of RISC function. RNA 13:723–730.
18. Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M (2007) Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature 449:919–922.
19. Lu Y, Xiao J, Lin H, Bai Y, Luo X, Wang Z, Yang B (2009) Complex antisense inhibitors offer a superior approach for microRNA research and therapy. Nucleic Acids Res 37:e24–e33.
20. Gao H, Xiao J, Sun Q, Lin H, Bai Y, Yang L, Yang B, Wang H, Wang Z (2006) A single decoy oligodeoxynucleotides targeting multiple oncoproteins produces strong anticancer effects. Mol Pharmacol 70:1621–1629.
21. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065–7070.
22. Henkel J (1999) Attacking AIDS with a ‘cocktail’ therapy? FDA Consum 33:12–17.
23. Konlee M (1998) An evaluation of drug cocktail combinations for their immunological value in preventing/remitting opportunistic infections. Posit Health News 16:2–4.
24. Charpentier G (2002) Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 18(Suppl 3):S70–S76.
25. Ogihara T (2003) The combination therapy of hypertension to prevent cardiovascular events (COPE) trial: rationale and design. Hypertens Res 28:331–338.
26. Kumar P (2005) Combination treatment significantly enhances the efficacy of antitumor therapy by preferentially targeting angiogenesis. Lab Investig 85:756–767.
27. Nabholtz JM, Gligorov J (2005) Docetaxel/ trastuzumab combination therapy for the treatment of breast cancer. Expert Opin Pharmacother 6:1555–1564.